TTPH News Alert Tetraphase Pharmaceuticals Inc (TTPH) 38.86 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tetraphase Pharmaceuticals Inc (TTPH) 38.86 $TTPH

Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 104.59 (+0.31), TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:47AM CST

NETE: 1.20 (unch), TTPH: 38.86 (+0.53), NES: 4.96 (-0.44), OVAS: 43.73 (+3.22), MCEP: 6.07 (-0.12), FMD: 5.06 (unch), ISIG: 3.78 (+0.02), WOR: 30.41 (+0.34), IMNP: 1.89 (+0.02), GLRI: 4.20 (+0.16), MBT: 8.11 (+0.06), NDRO: 4.84 (-0.05), OBCI: 4.55 (+0.03), INS: 1.56 (-0.01), SIMG: 5.31 (-0.07), KEG: 1.73 (+0.01), MPO: 1.63 (-0.05), TRXC: 2.79 (+0.03), CRK: 7.01 (-0.20), ZAGG: 6.66 (+0.13)

Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Taking Wall Street by Storm: Special Coverage on Tetraphase, Oracle, Jabil, Paramount and Target
PR Newswire - Thu Dec 18, 8:28AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Tetraphase (NASDAQ: TTPH), Oracle (NYSE: ORCL), Jabil (NYSE: JBL), Paramount (NYSE MKT: PZG), and Target (NYSE: TGT). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TTPH: 38.86 (+0.53), PZG: 1.00 (+0.06), TGT: 74.65 (-0.04), JBL: 21.88 (+0.17), ORCL: 46.23 (+0.22)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST

VIP: 4.07 (-0.26), TTPH: 38.86 (+0.53), FRO: 2.43 (-0.01), EXXI: 3.45 (-0.22), OVAS: 43.73 (+3.22), EOX: 1.33 (+0.05), NVGN: 2.40 (-0.09), WLT: 1.45 (-0.02), AKS: 5.76 (+0.11), MBT: 8.11 (+0.06), NADL: 1.68 (-0.08), NQ: 4.32 (-0.36), RVLT: 1.28 (-0.02), SSE: 6.64 (-0.03), AREX: 6.98 (-0.11), RAD: 7.26 (-0.09), AGEN: 3.85 (unch), PBR: 7.60 (-0.11), DNKN: 41.85 (-0.13), GDP: 4.93 (-0.22), SIMG: 5.31 (-0.07), KEG: 1.73 (+0.01), LINE: 10.93 (-0.32)

Market Maker Surveillance Report. SFY, NES, GASL, MDBX, TTPH, XNCR, Winning Stocks With Lowest Price Friction For Wednesday, December 17th 2014
M2 - Thu Dec 18, 12:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4931 companies with "abnormal" market making, 4995 companies with positive Friction Factors and 2119 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Swift Energy Co (NYSE:SFY), M/S GBCPN 3 GBL INDS (NYSE:NES), Direxion Daily Natural Gas Related Bull 2x Shares (NYSE:GASL), (OTC:MDBX), (NASDAQ:TTPH), (NASDAQ:XNCR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
TTPH: 38.86 (+0.53), GASL: 4.67 (-0.22), NES: 4.96 (-0.44), SFY: 4.47 (-0.06), XNCR: 16.83 (+0.77)

TETRAPHASE PHARMA
at Investor's Business Daily - Wed Dec 17, 5:50PM CST
TETRAPHASE PHARMA (TTPH) rose 14.5% to 37.99 after unveiling positive phase 3 trial results on eravacycline for treating intra-abdominal infections. The developer of antibiotics for resistant infections had closed up 10.6% to 33.19, a new high.
TTPH: 38.86 (+0.53)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 4:40PM CST

E: 36.10 (-0.25), TTPH: 38.86 (+0.53), RCAP: 11.23 (+0.26), PKD: 3.11 (+0.03), RUSS: 24.00 (-2.60), GTI: 4.84 (-0.04), AKS: 5.76 (+0.11), REI: 10.95 (+0.22), ORCL: 46.23 (+0.22), ZAGG: 6.66 (+0.13)

Tetraphase antibiotic non-inferior to ertapenem in Phase 3 study
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:44PM CST

TTPH: 38.86 (+0.53)

Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
Business Wire - Wed Dec 17, 3:01PM CST
----Company to host conference call at 4:30 p.m. ET today -
TTPH: 38.86 (+0.53)

3 Momentum Stocks Undeterred by a Shaky Market - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Dec 16, 10:04AM CST
These stocks look to be a great play when the market has been trapped in the vicious circle of oil trading.
PTRY: 36.78 (+0.28), TTPH: 38.86 (+0.53), BBW: 19.35 (+0.25)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:18AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Inogen Leases Texas Facility, Lower Costs to Drive Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 11:20AM CST
Inogen Inc (INGN) recently agreed to lease approximately 23,890 square feet area in Richardson, TX.
TTPH: 38.86 (+0.53), PHG: 29.39 (-0.06), IVC: 16.80 (+0.20), INGN: 29.99 (-0.09)

Community-Acquired Infections Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxr44r/communityacquired) has announced the addition of the "Community-Acquired Infections Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Infections Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Pfizer Inc. - Panacea Biotec Limited - Daiichi Sankyo Company, Limited - Tetraphase Pharmaceuticals Inc. - TaiGen Biopharmaceuticals Holdings Limited - Janssen Research & Development, LLC - Dong Wha Pharma Co., Ltd. - Cubist Pharmaceuticals, Inc. - Belpharma S.A. Clinical Trial Overview of Top Institutes / Government - Hanyang University Medical Center - Ewha Womans University - Kyungpook National University - Katholieke Universiteit Leuven - Rennes University Hospital - University of Milan For more information visit http://www.researchandmarkets.com/research/hx...tyacquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TTPH: 38.86 (+0.53), CBSTZ: 0.06 (+0.01), PFE: 31.42 (-0.03), GSK: 42.85 (+0.11)

Tetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:30AM CST
Tetraphase Pharmaceuticals, Inc. (TTPH) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
LCI: 42.29 (+1.79), TTPH: 38.86 (+0.53), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)

Strong Portfolio, Dividends Make Merck An Attractive Opportunity
Kanak Kanti De - at Seeking Alpha - Mon Dec 08, 2:40PM CST

TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), RTGN: 3.65 (+0.10)

Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11 at 1:00 p.m. Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York.
TTPH: 38.86 (+0.53)

SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
GlobeNewswire - Wed Dec 03, 8:24AM CST
SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase Pharmaceuticals, Inc., and Dr. Taglietti is former Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories, Inc. In addition, the Company announced that Mounia Chaoui, Ph.D., has resigned from the Board of Directors.
TTPH: 38.86 (+0.53), SCYX: 10.49 (+0.65), FRX: 99.00 (-0.77)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 94

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading